Acalabrutinib Maleate
The maleate salt formulation of acalabrutinib, a BTK inhibitor used to treat B-cell blood cancers with the same mechanism of action and safety profile as acalabrutinib. It is taken orally twice daily and should not be combined with strong acid-reducing agents that can impair its absorption. Monitoring for cardiac rhythm disturbances and bleeding is recommended throughout therapy.
Peso Molecular
581,6000 g/mol
TPSA
193,00 Ų
Áreas Terapêuticas
Mecanismo de Ação
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O
InChI
InChI=1S/C26H23N7O2.C4H4O4/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20;5-3(6)1-2-4(7)8/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35);1-2H,(H,5,6)(H,7,8)/b;2-1-/t19-;/m0./s1
Molecular Formula
C30H27N7O6
HBD / HBA
4 / 10
Ligações Rotacionáveis
6
Átomos Pesados
43
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
The maleate salt formulation of acalabrutinib, a BTK inhibitor used to treat B-cell blood cancers with the same mechanism of action and safety profile as acalabrutinib. It is taken orally twice daily and should not be combined with strong acid-reducing agents that can impair its absorption. Monitoring for cardiac rhythm disturbances and bleeding is recommended throughout therapy.
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Yes, Acalabrutinib Maleate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594293. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 126506029. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="acalabrutinib-maleate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/acalabrutinib-maleate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/acalabrutinib-maleate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/acalabrutinib-maleate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="acalabrutinib-maleate"></drugfyi-drug>